Today's Research Reports on Stocks to Watch: GlaxoSmithKline and Novartis
NEW YORK, NY / ACCESSWIRE / May 16, 2017 / GlaxoSmithKline and Novartis shares traded flat on Monday despite news revealing that Glaxo could be ready to buy out Novartis' stake in their joint venture for about $10 billion.
RDI Initiates Coverage on:
Novartis AG
https://ub.rdinvesting.com/news/?ticker=NVS
GlaxoSmithKline plc
https://ub.rdinvesting.com/news/?ticker=GSK
Shares of Novartis AG saw a modest 0.12% close on Monday but according to news, Novartis could be inching closer to what could be a major takeover of Astrazeneca. Novartis and GlaxoSmithKline have a consumer healthcare joint venture of which GlaxoSmithKline is considering to buyout Novartis' share. According to the Sunday Times, if Novartis sells its 36.5% stake in the venture, it could open up funds for the Swiss drugmaker to purchase Astrazeneca. Rumors already started swirling last year that Novartis would take up a bid for Astrazeneca. Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
Access RDI's Novartis Research Report at:
https://ub.rdinvesting.com/news/?ticker=NVS
GlaxoSmithKline plc's shares closed up 0.30% yesterday on mediocre volume but big news revealed that the British drug maker could be getting ready to buy out its partner, Novartis. The two have a consumer healthcare joint venture where Novartis owns 36.5%. Next March the company will have the option to buy out this stake and it would then give GSK control of the biggest consumer health operations in the world. According to an investor speaking to the Times, GSK has "been consistent all along that this is a business they want to own, and will move forward when the time is right." Glaxo CEO, Emma Walmsley, confirmed that the company wants to hang on to the business on the company's first-quarter earnings call. Glaxo also announced this month that its inhaled medicine Breo proved significantly better than standard care in helping people with asthma. Eric Dube who is the head GSK's respiratory franchise, said that the study showed that patients initiated with Breo treatment had twice the odds of achieving an improvement in asthma control compared to those patients who continued their usual care in the study in everyday clinical practice.
Access RDI's GlaxoSmithKline Research Report at:
https://ub.rdinvesting.com/news/?ticker=GSK
Our Actionable Research on Novartis AG (NYSE: NVS) and GlaxoSmithKline plc (NYSE: GSK) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
